Our Clinical Data

European studies have shown sustained IOP reduction, lower medication needs and minimal safety events for at least five years post-procedure1, including:

35% median
intraocular pressure
reduction (with cataract,
1-8 year studies)1

Mid-teens end-IOP1

Significant
medication reduction
across a broad range
of patients1

Low adverse
event rate (self-limited,
non-sight-threatening)1

We partner with leaders in glaucoma patient care, technology, and research. View our Medical Advisory Board.

1. Durr GM, Töteberg-Harms M, Lewis R, Fea A, Marlolo P, Ahmed IIK, Current Review of Excimer Laser Trabeculostomy. Eye and Vis 7, 24 (2020).